Table 2. Relative Risks and PAFs for Receiving Prescription Opioids by BMI Category in 565 930 Patients Aged 35 to 64 Years, athenahealth Network 2015 to 2017a.
BMI categoryb | Relative risk (95% CI)c,d | PAF, % (95% CI)c |
---|---|---|
Underweight | 1.15 (1.10-1.21) | 0.2 (0.2-0.3) |
Normal weight | 1 [Reference] | |
Overweight | 1.08 (1.06-1.10) | 2.1 (1.6-2.6) |
Obese | ||
I | 1.24 (1.22-1.26) | 5.0 (4.6-5.4) |
II | 1.33 (1.30-1.36) | 3.9 (3.6-4.2) |
III | 1.48 (1.45-1.51) | 3.9 (3.7-4.2) |
IV | 1.71 (1.65-1.77) | 1.3 (1.2-1.5) |
Total (overweight to obese IV) | NA | 16.2 (15.0-17.4) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); NA, not applicable; PAF, population-attributable fraction.
eTable 1 in the Supplement provides the complete regression results. Sample interpretation: 5.0% of patients receiving prescription opioids could be avoided in the hypothetical situation in which those with a BMI of obese I had a normal BMI.
Underweight: BMI, 18.5 to 19.9; normal weight: 20.0 to 24.9; overweight: 25.0 to 29.9; obese I: 30.0 to 34.9; obese II: 35.0 to 39.9; obese III: 40.0 to 49.9; and obese IV: 50.0 to 80.0.
Adjusted for age, sex, race/ethnicity, region, urbanicity, and health insurance.
Relative risk calculated using a negative binomial model with robust SEs.